Stella Xu, Ph.D.

Stella Xu, Ph.D.   |   Director

Stella Xu, Ph.D. has served as a member of our board of directors since November 2018. Dr. Xu has served as Managing Director of Quan Capital, a life sciences venture fund with offices in China and the United States, since August 2017. Prior to joining Quan Capital, Dr. Xu served as Vice President and site head of Roche Innovation Center Shanghai, and a member of the global management team for Roche’s Immunology, Inflammation & Infectious Diseases Discovery and Translation Area, from September 2012 to August 2017. Dr. Xu joined Roche from McKinsey & Company. Dr. Xu has also served as a director of Centrexion Therapeutics Corporation, a biopharmaceutical company focused on the treatment of chronic pain, since January 2018 and previously served as a director of ARMO BioSciences, Inc., a late-stage biopharmaceutical company focused on immuno-oncology, from August 2017 to July 2018 when it was acquired by Eli Lilly and Company. Dr. Xu received a B.S. in biophysics from Peking University and a Ph.D. in immunology from Northwestern University. • David Kabakoff, Ph.D.
Chairman
• Elaine V. Jones, Ph.D.
Director
• Chau Q. Khuong
Director
• Judith J. Li
Director
• Briggs Morrison, M.D.
Director
• Tim Shannon, M.D.
Director
• Stephen Webster
Director
• Stella Xu, Ph.D.
Director